Kheth'Impilo, Woodstock, Cape Town, South Africa.
J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):e60-7. doi: 10.1097/QAI.0b013e3182303c7e.
Few studies describe temporal trends in pediatric antiretroviral treatment (ART) programs in sub-Saharan Africa. Adult studies show deteriorating patient retention in recent years. We describe temporal trends in baseline characteristics and treatment outcomes amongst ART-naive children between 2004 and 2009 at 30 facilities in 4 South African provinces.
Linear trend in baseline parameters between annual enrolment cohorts was assessed. Corrected mortality estimates were calculated, correcting for deaths amongst those lost to follow-up using probability-weighted Kaplan-Meier functions. On-treatment immunologic changes were modelled using generalized estimating equations.
Three thousand and seven children (median age 6.4 years) were included. Monthly enrollment increased from 1.9 children in 2004 to 106 in 2009. Proportions with severe baseline immunodeficiency decreased from 85.5% to 64.5% between 2004/2005 and 2009, P < 0.0005. Proportions with baseline World Health Organization clinical stages III and IV reduced from 72.9% to 49.0% between 2006 and 2009, P < 0.0005. Later calendar cohorts had independently and progressively reduced on-treatment probabilities of severe immunodeficiency despite adjusting for baseline immunological status, adjusted odds ratio: 0.38 [confidence interval (CI): 0.26 to 0.55; P < 0.0005; 2008/2009 compared with 2004/2005]. After 24 months, corrected mortality was 6.1% (CI: 5.1% to 7.3%) and loss to follow-up was 6.8% (CI: 5.7% to 8.2%), with no deterioration amongst more recently enrolled cohorts (P = 0.50 and P = 0.55, respectively). After 4 years, program retention was 84.1% (CI: 80.9% to 86.7%).
Childrens' baseline condition when starting ART has improved considerably. Improving immunological treatment outcomes, the high medium-term patient retention with lack of temporal deterioration despite rapid patient number increases, provide evidence that pediatric ART programs are increasingly effective for those accessing them. However, children must start treatment when younger, following current international guidelines.
在撒哈拉以南非洲,很少有研究描述儿科抗逆转录病毒治疗 (ART) 项目的时间趋势。成人研究表明,近年来患者保留率恶化。我们描述了在 2004 年至 2009 年期间,4 个南非省的 30 个设施中,3000 名初次接受 ART 的儿童的基线特征和治疗结果的时间趋势。
评估每年入组队列之间基线参数的线性趋势。使用概率加权 Kaplan-Meier 函数校正因失访而死亡的患者,计算校正死亡率估计值。使用广义估计方程模型对治疗中的免疫变化进行建模。
共纳入 3700 名儿童(中位年龄 6.4 岁)。每月入组人数从 2004 年的 1.9 人增加到 2009 年的 106 人。严重基线免疫缺陷的比例从 2004/2005 年的 85.5%降至 2009 年的 64.5%,P<0.0005。2006 年至 2009 年间,基线世界卫生组织临床分期 III 和 IV 的比例从 72.9%降至 49.0%,P<0.0005。尽管调整了基线免疫状态,但较晚的日历队列在治疗中仍具有独立且逐渐降低的严重免疫缺陷的可能性,校正比值比:0.38[置信区间 (CI):0.26 至 0.55;P<0.0005;2008/2009 年与 2004/2005 年相比]。24 个月后,校正死亡率为 6.1%(CI:5.1%至 7.3%),失访率为 6.8%(CI:5.7%至 8.2%),最近入组的队列中没有恶化(P=0.50 和 P=0.55)。4 年后,项目保留率为 84.1%(CI:80.9%至 86.7%)。
儿童开始接受 ART 时的基线情况有了显著改善。免疫治疗结果的改善、中短期患者保留率高,尽管患者人数迅速增加,但没有出现时间恶化,这为儿科 ART 项目对接受治疗的患者越来越有效提供了证据。然而,儿童必须按照当前的国际指南,在更年轻时开始治疗。